The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
This study aims to explore how the website, the Driving and Dementia Roadmap (DDR), is experienced by and impacts how people with dementia and family/friend carers manage the driving cessation process. Participants will be asked to use the DDR for 2-6 weeks, record their thoughts in a diary and take part in an interview or focus group.
- Are a person living with dementia who is still driving or has stopped driving within the past 2 years
- Are family member or friend who is caring for or providing support to a person with dementia who is still driving or has stopped driving within the past two years
- Are a healthcare provider who cares for people living with dementia
- Ability to speak English
Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The overall aim of the current study is to evaluate a newly developed app that focuses on providing stress-management strategies for family caregivers of people living with dementia. Findings from the study of an app that aims to address the stressors associated with caregiving has the potential to improve the quality of life of caregivers of people living with dementia.
- Providing informal and unpaid care (e.g., spouses, children) for people living with dementia
- Providing primary care (i.e., most of the care or equally shares the care with another individual such as a mother or sibling) for the person living with dementia
- Own a smartphone (e.g., iPhone, Android)
- Not currently using a mobile app created for caregivers
- Ability to speak English
Surveying opinions on how to improve diversity in dementia research.
You are eligible to participate if you are:
1) Involved in dementia research or services
AND / OR
2) from an underserved group* in dementia research.
3)Aged 19 +
3)Able to complete the web-based survey in one of the following languages: English, French, Chinese (simplified), Punjabi, Inuktitut.
*Underserved groups in dementia research include: Racial/ethnic minorities (i.e., South Asian, Chinese, Black, Filipino, Arab, Latin American, Southeast Asian, West Asian, Korean, Japanese, or other racial/ethnic minority) Indigenous populations (i.e., First Nations, Inuit, Métis, or other Indigenous group), Sexual/gender minorities (i.e., the LGBTQ2S+ community), Individuals living in rural and/or remote communities, Individuals living with a disability, Individuals with low social and economic conditions.
A dementia diagnosis impacts the cognitive, functional, and physical abilities of those diagnosed, which will influence their ability to perform activities of daily living including meal preparation and eating. Persons living with dementia can experience a range of difficulties while eating that will impact their ability to consume adequate food and fluids, which include but are not limited to swallowing, chewing, and self-feeding difficulties. Consequently, persons living with dementia are at increased risk of malnutrition and negative health outcomes. The objective of this study is to understand the experience of persons’ living with dementia or diagnosed memory problems and/or their caregivers in managing eating challenges and swallowing problems in the community.
You are eligible to participate if you:
- Speak English
- A person with memory problems experiencing eating challenges or swallowing problems in the community
- OR if you are or were a caregiver to a person with memory problems with eating challenges or swallowing problems.
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
60+
Diagnosis of Alzheimer's disease
Must have a study partner
The goal of the proposed SYNERGIC-2 TRIAL (SYNchronizing Exercises, and Remedies to GaIn Cognition@home) is to evaluate cognitive improvements from personalized multidomain interventions that target multiple dementia risk factors delivered at home to older adults with Mild Cognitive Impairment (MCI).
- Aged 60-85 years.
- Concerned about memory or thinking problems.
- Have access to internet at home.
- Ability to speak English.
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
To examine the effects of a stress management program on well-being, stress, and cognition in family caregivers of someone with dementia or a related neurodegenerative disorder. We will be recruiting participants from 2023 - 2027.
- are a primary family caregiver of a person with dementia or a related neurodegenerative disorder.
- have access to a computer with high-speed internet; and feel comfortable using email and Zoom (a secure online meeting platform).
- have a video camera on your device. To ensure safety of participants during the program sessions, it is important that participants turn on their video camera. Keeping the video camera on is also important to build trust within the group sessions and when interacting with the researchers.
- are willing to be randomised to one of 3 groups, even if it is not your preferred group.
- are able to commit to a synchronous 8-week online group-based program (described below) and complete daily prescribed daily home practices.
- are able to commit to three assessment sessions: one baseline assessment, one post-program assessment, one 12-month follow-up assessment.
- agree to audio recording of interview sessions and portions of the assessment that require accurate verbal data collection.
- are able to provide blood samples, potentially after a 12-hour fast.
- are able to travel to a LifeLabs clinic for biomarker collection.
- agree to refrain from participating in new studies or programs during the 8-week study session.
- meet the screening criteria during the pre-screening interview.
- ability to speak English.
Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.
Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.
Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.
Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.
Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.
Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.
Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.
Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.
Have not undergone any significant head trauma or surgery in the past 6 months.
Are not pregnant or planning to become pregnant during the duration of the study.
Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.
Ability to speak English and French
Follow us: